Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2296295 | 1.00 | CHRM2 (0.49) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL707002 | 0.82 | SIGMAR1 (0.43) | — | |
| SCHEMBL2297682 | 0.76 | HTR1A (0.57) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL2296304 | 0.73 | HTR1B (0.66) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL2296297 | 0.73 | HTR1B (0.66) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL2296298 | 0.71 | CHRM2 (0.52) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL17707490 | 0.69 | SLC6A2 (0.61) | SLC6A2SLC6A3 | |
| SCHEMBL23189353 | 0.69 | HTR1A (0.57) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL6285597 | 0.69 | NR4A2 (0.46) | GABRA1GABRB2 | |
| SCHEMBL14472988 | 0.68 | HTR1B (0.71) | CHRM2HTR1AADRA2ACHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633239-B2 | Process for the preparation of eletriptan | BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2014-01-21 | — | — | US | disclosed |
| EP-2349998-B1 | A NOVEL PROCESS FOR THE PREPARATION OF ELETRIPTAN | BIOPHORE INDIA PHARMACEUTICALS PVT LTD (IN) | 2013-07-17 | — | — | EP | disclosed |
| US-20110207943-A1 | NOVEL PROCESS FOR THE PREPARATION OF ELETRIPTAN | BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2011-08-25 | — | — | US | disclosed |
| EP-2349998-A2 | A NOVEL PROCESS FOR THE PREPARATION OF ELETRIPTAN | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010049952-A2 | A NOVEL PROCESS FOR THE PREPARATION OF 5-SUBSTITUTED INDOLE DERIVATIVES | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207943-A1 | NOVEL PROCESS FOR THE PREPARATION OF ELETRIPTAN | HTR3C, HTR3A, HTR1A | CHRM2 1485/4885HTR1A 3/4885ADRA2A 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.